PremiumCompany AnnouncementsMirum Pharmaceuticals’ Earnings Call Highlights Growth and Future Prospects Mirum Pharmaceuticals price target raised to $65 from $63 at Morgan Stanley Mirum Pharmaceuticals price target raised to $55 from $50 at Baird PremiumThe FlyMirum Pharmaceuticals reports FY24 EPS ($1.85), consensus ($1.42) Mirum Pharmaceuticals sees FY25 product sales of $420M-$435M vs. $336.4M in FY24 Mirum Pharmaceuticals announces FDA approval for Ctexli tablets PremiumThe FlyMirum Pharmaceuticals sees FY25 revenue $420M-$435M, consensus $418.15M Mirum Pharmaceuticals Surpasses 2024 Sales Guidance Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities 
